Advertisement

Topics

Genmab Inc. Company Profile

18:01 EDT 23rd September 2017 | BioPortfolio

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.’s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is an international company with operations in Europe and the United States.

Location

457 North Harrison Street
Princeton
New Jersey
08540
United States of America

Contact

Phone: 1 609 430-2481
Fax: 1 609 430-2482
Email: info@genmab.com


News Articles [58 Associated News Articles listed on BioPortfolio]

Genmab A/S: Genmab to Present at Morgan Stanley 15th Annual Global Healthcare Conference

Media ReleaseCopenhagen, Denmark; September 5, 2017 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will give a company update at the Morgan Stanley 15...

Genmab A/S: Genmab to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Media ReleaseCopenhagen, Denmark; May 30, 2017 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 38th ...

Genmab A/S: Grant of Restricted Stock Units and Warrants to Genmab employees

Company AnnouncementCopenhagen, Denmark; June 8, 2017 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 1,697 restricted stock units and 5,224...

Darzalex drives Genmab growth but profits miss

Danish biotech firm Genmab dwarfed its 2016 sales with both its half-year and quarterly figures, which…

Genmab A/S: Genmab Announces Financial Results for the First Quarter of 2017

May 10, 2017; Copenhagen, Denmark; Interim Report for the First Quarter of 2017Highlights -- USD 255 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 211 million .....

Phase III Success for Janssen and Genmab with Frontline Myeloma Antibody

Results from a Phase III study with Janssen’s blockbuster daratumumab could lead to its approval as a first-line treatment for patients with multiple myeloma.  Danish Genmab has announced today...

Genmab A/S: Genmab Announces Financial Results for the First Half of 2017

August 9, 2017; Copenhagen, Denmark;Interim Report for the First Half of 2017Highlights -- USD 554 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 454 million --.....

Genmab A/S: Genmab Announces Plans for New Studies of Daratumumab

Company Announcement -- 3 new Phase III studies of daratumumab planned in multiple myeloma and amyloidosis -- Studies planned to start between second half 2017 and first quarter 2018Copenhagen, Den...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Genmab Inc.

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat c...

Genmab A/S

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Den...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "Genmab Inc." on BioPortfolio

We have published hundreds of Genmab Inc. news stories on BioPortfolio along with dozens of Genmab Inc. Clinical Trials and PubMed Articles about Genmab Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genmab Inc. Companies in our database. You can also find out about relevant Genmab Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record